GLP peptides — glucagon-like peptides — have one of the most well-documented research histories in modern endocrinology. From their initial discovery in gut tissue extracts to their emergence as central subjects in metabolic, gastrointestinal, and longevity research, the GLP peptide family has been studied for over four decades. Understanding how long GLP peptides have been available — and how that research has evolved — helps laboratory researchers contextualize current preclinical models and appreciate the depth of mechanistic data now available.
The timeline of GLP peptide research spans multiple scientific eras: early hormonal discovery work in the 1980s, receptor identification through the 1990s, expanded preclinical exploration in the 2000s, and the emergence of novel GLP analogs like GLP-3 in more recent years. Each phase has added new layers to our understanding of how these signaling molecules interact with metabolic, intestinal, and cellular systems.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.
GLP-1 (S) 20MG — Research-Grade Reference Material GLP-1 (S) 20MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GLP-1 (S) 15MG
$75.00$56.25 with 1st order
GLOW (GHK-CU, BPC-157 & TB-500) 70MG
$95.00$71.25 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
Frequently Asked Questions
When were GLP peptides first discovered?
GLP-1 was first identified in the early 1980s following the sequencing of the proglucagon gene. Researchers discovered that the gene encoded not just glucagon, but additional peptide sequences that were later characterized as glucagon-like peptide-1 and glucagon-like peptide-2. GLP-2 was formally characterized through the late 1980s and 1990s.
How long has GLP-1 been studied in research?
GLP-1 has been an active subject of scientific research since approximately 1983–1986, when its amino acid sequence was first reported. That gives it over 40 years of research history, during which studies have investigated its role in insulin secretion, appetite signaling, and metabolic regulation.
When was GLP-2 first studied?
GLP-2 was identified alongside GLP-1 from the proglucagon gene in the 1980s, but its specific intestinotrophic properties were not characterized until the mid-1990s. A landmark study in 1996 demonstrated that GLP-2 promotes intestinal epithelial growth, opening a new branch of gut-focused research.
What is GLP-3 and when did research on it begin?
GLP-3 (also referred to in research contexts as retatrutide-related or novel GLP receptor agonist sequences) represents a newer generation of GLP-related peptide research. Serious investigation into extended GLP receptor family analogs has intensified primarily in the 2010s and 2020s, though the underlying receptor targets were identified earlier.
Are GLP peptides available for laboratory research today?
Yes. GLP-1, GLP-2, and GLP-3 analogs are available as research-grade peptides for laboratory use. These are supplied for in vitro and preclinical research models only and are not intended for human consumption.
What has research on GLP peptides focused on over the decades?
Research has shifted over time. Early studies focused on GLP-1’s incretin effects and glucose metabolism. The 1990s brought GLP-2 gut biology into focus. The 2000s and 2010s expanded into obesity, neurological signaling, and gut-brain axis research. More recently, multi-receptor GLP agonist analogs have become major research interests.
How does the research history of GLP peptides compare to other peptides?
GLP peptides have one of the longest and most extensively documented research histories among signaling peptides. Compounds like BPC-157 and TB-500 have been studied since the 1990s, while GLP-1 predates both by nearly a decade, giving the GLP family a particularly deep evidence base in preclinical literature.
The Origin: Proglucagon Gene Discovery (1980s)
The story of GLP peptides begins not with the peptides themselves, but with a gene. In the early 1980s, molecular biology had advanced to the point where scientists could sequence the proglucagon gene — the gene responsible for producing glucagon, a hormone central to blood sugar regulation. When researchers fully mapped this gene, they made a striking discovery: it encoded far more than glucagon alone.
GLP-1 (S) 20MG — Research-Grade Reference Material GLP-1 (S) 20MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GLP-1 (S) 15MG
$75.00$56.25 with 1st order
GLOW (GHK-CU, BPC-157 & TB-500) 70MG
$95.00$71.25 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
Embedded within the proglucagon sequence were two additional peptide structures that bore structural similarity to glucagon but had distinct amino acid compositions. These were designated glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2). The initial sequencing work, published in landmark papers between 1983 and 1986, established the molecular foundation for decades of research to come.
At this stage, GLP peptides were theoretical constructs — identified genetically but not yet well characterized in terms of biological function. The research community quickly moved to understand how and where these peptides were processed, secreted, and what receptors they engaged.
GLP-1: Early Functional Characterization
By the mid-to-late 1980s, research groups had identified that GLP-1 was secreted from intestinal L-cells in response to nutrient intake. Studies investigated its role as an “incretin” — a hormone capable of stimulating insulin release in a glucose-dependent manner. This mechanism attracted significant scientific interest because of its potential relevance to metabolic physiology, and GLP-1 became one of the most actively studied gut-derived signaling peptides of its era.
The 1990s: Receptor Mapping and Gut Biology Advances
The 1990s represented a critical expansion phase in GLP peptide research. With the basic molecular identities of GLP-1 and GLP-2 established, scientists turned their attention to receptor identification, tissue distribution, and functional biology.
GLP-1 Receptor Cloning
In 1992, the GLP-1 receptor was successfully cloned, providing researchers with a defined molecular target for studying GLP-1’s mechanisms of action. This was a pivotal moment — receptor cloning enabled preclinical studies using cell-based assays and opened the door to systematic investigation of GLP-1 signaling pathways. Research through the 1990s investigated how GLP-1 influenced beta-cell function, gastric emptying, and satiety signaling, establishing a rich preclinical literature.
GLP-2 and the Intestinotrophic Discovery
While GLP-1 attracted the bulk of metabolic research attention, GLP-2 emerged from the shadow of its sibling peptide with its own landmark discovery. A highly cited 1996 study demonstrated that GLP-2 had potent intestinotrophic properties — meaning it promoted the growth and maintenance of intestinal epithelial tissue. This finding repositioned GLP-2 as a subject of intense gut biology research, with studies exploring its role in mucosal healing, nutrient absorption, and intestinal integrity.
Research through the late 1990s continued to map GLP-2 receptor expression in intestinal tissue, and investigators began exploring how GLP-2 signaling influenced villus height, crypt cell proliferation, and intestinal barrier function in preclinical models.
GLP-2 (T) 45MG for laboratory research →
The 2000s: Preclinical Expansion and Analog Development
Entering the 2000s, GLP peptide research broadened considerably. The preclinical literature grew rapidly, with studies examining GLP-1 and GLP-2 in increasingly diverse research contexts. Investigators explored gut-brain axis signaling, neuroprotective properties, inflammatory modulation, and the behavior of GLP peptides in various disease models.
GLP-1 in Neurological Research
One of the most unexpected expansions of GLP-1 research in the 2000s was into neurological territory. Studies found GLP-1 receptor expression in the central nervous system, prompting investigations into GLP-1’s potential role in neuroprotection, synaptic signaling, and cognitive function. Preclinical models examined GLP-1 receptor agonism in neurodegenerative contexts, adding a neurological dimension to what had previously been viewed primarily as a metabolic peptide family.
Analog Research Begins
The 2000s also saw the development and preclinical study of modified GLP analogs — peptide sequences engineered for extended half-life, enhanced receptor binding, or modified tissue distribution. Research on these analogs generated extensive data on structure-activity relationships and receptor selectivity, greatly expanding the toolkit available to metabolic researchers.
GLP-1 (S) 20MG for research applications →
The 2010s: Dual and Triple Receptor Agonist Research
By the 2010s, GLP peptide research had matured enough that scientists began systematically exploring multi-receptor targeting strategies. Rather than studying GLP-1 or GLP-2 in isolation, researchers investigated how simultaneous engagement of multiple receptors — such as GLP-1 combined with GIP (glucose-dependent insulinotropic polypeptide) or glucagon receptors — could produce distinct effects in metabolic models.
The GLP-3 Research Emergence
Within this context of expanding receptor pharmacology, research interest in GLP-3 and related novel GLP receptor agonist sequences gained momentum. While the term “GLP-3” as used in modern peptide research contexts refers to next-generation multi-receptor targeting analogs (sometimes associated with retatrutide-class molecules), the underlying receptor biology it engages had been incrementally characterized over the prior two decades. The 2010s saw a meaningful acceleration in studies investigating these molecules in obesity, metabolic, and inflammation models.
Research laboratories began studying triple agonist sequences that could simultaneously engage GLP-1, GIP, and glucagon receptors, generating early preclinical data on their effects on body composition, energy expenditure, and lipid metabolism in animal models.
GLP-3 (R) 60MG for advanced metabolic research →
The 2020s: Research-Grade GLP Peptides and Modern Laboratory Use
Today, GLP peptides represent one of the most actively researched peptide families in existence. Researchers now have access to GLP-1, GLP-2, and GLP-3 analogs as research-grade compounds for preclinical and laboratory use. The depth of background literature available to support experimental design is extraordinary — spanning more than 40 years for GLP-1 and GLP-2, and a rapidly growing body of data for newer GLP-3 class molecules.
What Modern GLP Research Investigates
Current preclinical GLP research spans a wide range of biological questions:
- Metabolic signaling and energy homeostasis in rodent models
- Intestinal barrier integrity and mucosal biology (GLP-2 focus)
- Neuroinflammation and gut-brain axis signaling (GLP-1 focus)
- Receptor selectivity and binding kinetics of novel GLP analogs
- Multi-receptor agonism and additive or synergistic effects (GLP-3 focus)
- Inflammatory modulation across gastrointestinal and systemic models
- Longevity-adjacent research exploring mitochondrial and cellular aging pathways
GLP Peptides in Research Stacks
Researchers have also begun examining GLP peptides in combination with other compounds. For example, studies have explored GLP peptides alongside mitochondrial signaling peptides like MOTS-c to investigate complementary metabolic effects. Others have examined GLP-2 in gut-repair contexts alongside peptides like BPC-157 that also have documented mucosal biology properties in preclinical models.
MOTS-C 40MG for mitochondrial signaling research →
GLP Research Timeline: A Summary Overview
| Era | Key Development | Primary Peptide Focus |
|---|---|---|
| 1983–1989 | Proglucagon gene sequencing; GLP-1 and GLP-2 identified | GLP-1, GLP-2 |
| 1990–1999 | GLP-1 receptor cloned (1992); GLP-2 intestinotrophic properties discovered (1996) | GLP-1, GLP-2 |
| 2000–2009 | Preclinical expansion; neurological GLP-1 research; analog development begins | GLP-1, GLP-2, early analogs |
| 2010–2019 | Dual/triple receptor agonist research; GLP-3 class molecules emerge | GLP-1, GLP-2, GLP-3 |
| 2020–present | Research-grade GLP analogs widely available; advanced metabolic and longevity models | GLP-1, GLP-2, GLP-3 |
Where These Fit in Your Research Library
If your research program involves metabolic signaling, gut biology, or multi-receptor GLP pharmacology, the following compounds represent key options for laboratory investigation:
GLP-1 (S) 20MG — foundational metabolic signaling research →
GLP-2 (T) 30MG — intestinal biology and mucosal research →
GLP-3 (R) 10MG — novel multi-receptor agonist research →
Researchers interested in the broader peptide catalog — including metabolic, cognitive, and tissue-repair compounds — can explore the full range of available research-grade peptides at SourcePeptides.co.
Final Takeaway
GLP peptides have been available to researchers in some form for over four decades. GLP-1 and GLP-2 were identified in the early 1980s from proglucagon gene sequencing, with receptor characterization, functional biology, and analog development unfolding progressively through the 1990s, 2000s, and 2010s. GLP-3 class analogs represent the newest frontier, with research accelerating meaningfully in the last ten years. Today, all three peptide families are available as research-grade compounds with substantial preclinical literature to support experimental design. For laboratory researchers studying metabolic signaling, gut biology, or next-generation receptor pharmacology, GLP peptides offer one of the deepest and most mature research foundations available in the peptide sciences.
Sources & Further Reading
- Bell et al. — “Sequence of the human glucagon gene” — Nature (1983)
- Thorens B — “Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1” — PNAS (1992)
- Drucker et al. — “Intestinal epithelial growth is stimulated by glucagon-like peptide 2” — PNAS (1996)
- PubMed Search — GLP-1 neuroprotection preclinical research
- PubMed Search — GLP triple agonist and retatrutide research
